Can less be more? new study tests cutting antibiotics in cancer patients with sepsis
NCT ID NCT03683329
First seen Jan 23, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This study looked at whether reducing the use of strong, broad-spectrum antibiotics in cancer patients with sepsis or septic shock is as safe as continuing them. The goal is to lower the risk of creating drug-resistant bacteria. Researchers compared a de-escalation strategy to standard antibiotic treatment in 398 patients in intensive care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL CARE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Paoli Calmettes
Marseille, 13273, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Antibiotic de-escalation strategy
What this could lead to
If successful, this could show that reducing antibiotic use in cancer patients with severe infections is safe, helping to slow the rise of drug-resistant bacteria.
What could go wrong
This is a completed trial, but results may not apply to all cancer patients. The strategy might not be as safe as standard care, and individual patient factors could affect outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.